Efficacy and safety of low-dose interleukin 2 in the treatment of moderate-to-severe bullous pemphigoid: A single center perspective-controlled trial.
J Am Acad Dermatol
; 2024 Aug 23.
Article
em En
| MEDLINE
| ID: mdl-39182680
ABSTRACT
BACKGROUND:
Regulatory T cells (Tregs) are reduced in the peripheral blood and skin lesions of patients with bullous pemphigoid (BP). Low-dose interleukin 2 (IL-2) therapy can stimulate Tregs specifically, suggesting potential for the treatment of BP.OBJECTIVE:
To evaluate the response to low-dose IL-2 therapy in the treatment of moderate-to-severe BP.METHODS:
Forty-three patients with moderate-to-severe BP were included. The therapy included systemic corticosteroids with an initial dose of 0.5 mg/kg/d for moderate and 1.0 mg/kg/d for severe disease, respectively, combined with allowed immunosuppressants for the control group, whereas in addition to the same corticosteroid therapy, IL-2 (half million IU) was administered subcutaneously every other day for the treatment group for 8 weeks. The primary outcome was the number of days required to achieve disease control. Secondary outcomes included other clinical responses.RESULTS:
The number of days required to achieve disease control with the treatment group was (7.60 ± 3.00), which was shorter than in the control group (10.43 ± 3.06) (P = .008). The total amount of systemic corticosteroids was less, and no serious infections were detected in the treatment group.LIMITATIONS:
Single center, open-label study with short duration and small size.CONCLUSION:
Our trial supports the potential of low-dose IL-2 therapy for patients with moderate-to-severe BP, which showed earlier treatment responses.
Texto completo:
1
Bases de dados:
MEDLINE
Idioma:
En
Revista:
J Am Acad Dermatol
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
China